Health News

New research suggests brain tumor patients who take the seizure drug valproic acid on top of standard treatment may live longer than people who take other kinds of epilepsy medications to control seizures.

Read more

Filed under: Pharmacy News
Tags: brain, Drug, Pharmacy, Tumor

Related posts

• Study In NEJM Shows Novartis Drug Afinitor® Reduces Size Of SEGAs, Benign Brain Tumors Associated With Tuberous Sclerosis (0)
  The New England Journal of Medicine (NEJM) published a study that found patients taking Afinitor® (everolimus) tablets experienced a decrease in the size of their subependymal giant cell astrocytoma (SEGA), a benign brain tumor associated with tuberous sclerosis (TS)(1,2)... Read more [tags] Pharmacy News [/tags]
  
  
• Scientists develop nanobioconjugate drug to target brain tumor (0)
  Nine years ago, scientists at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute detected a subtle shift occurring in the molecular makeup of the most aggressive type of brain tumors, glioblastoma multiforme. With further study, they found that a specific protein called laminin-411 plays a major role in a tumor's ability to build new blood vessels to support [...]
  
  
• Researcher tackles deadly brain tumors (0)
  Natalie Ciaccio, a fourth-year graduate student researcher in the Department of Pharmaceutical Chemistry at the University of Kansas, is investigating what might be an ideal target for anti-cancer drug therapy, and she is focusing her work on brain tumors specifically. Read more [tags] Pharmacy News [/tags]
  
  
• PTC Therapeutics Initiates Phase 2 Clinical Trial Of PTC299 In Patients With Neurofibromatosis Type 2 (0)
  PTC Therapeutics, Inc. (PTC) announced the initiation of a Phase 2 clinical trial of PTC299 in adult patients with neurofibromatosis type 2 (NF2), a rare genetic disorder that causes the development of non-malignant brain tumors. PTC299 is a novel, orally administered investigational new drug that is designed to selectively block tumor-related vascular endothelial growth factor [...]
  
  
• Phase III Trial Of Novartis Drug Afinitor® Met Primary Endpoint Of Reducing SEGA Tumor Size In Patients With Tuberous Sclerosis (0)
  Novartis Pharmaceuticals Corporation ("Novartis") announced Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6)... Read more [tags] Pharmacy News [/tags]